23andMe provides an FDA-authorized report screening for two specific genetic variants—G2019S in the LRRK2 gene and N370S in the GBA gene—associated with an increased risk of Parkinson’s disease. While these results identify a predisposition, they do not diagnose the disease, nor do they account for hundreds of other rare variants or environmental factors.
Genetic testing has transitioned from a specialized clinical procedure to a common household curiosity. For those concerned about neurodegenerative conditions, the Parkinson’s Disease Genetic Health Risk report is often the primary point of interest. However, interpreting these results requires a nuanced understanding of genetics, statistics, and the current limitations of consumer-grade biotechnology in 2026.
The Scientific Foundation: Genes Screened by 23andMe
The 23andMe Parkinson’s report focuses on two specific "risk variants." It is a common misconception that the test sequences the entire genome for every possible mutation related to the disease. Instead, it uses genotyping to look at specific locations in the DNA known as Single Nucleotide Polymorphisms (SNPs).
The LRRK2 Gene (G2019S Variant)
The LRRK2 (Leucine-Rich Repeat Kinase 2) gene provides instructions for making a protein called dardarin. This protein is involved in cell signaling and the movement of structures within cells. The G2019S variant is the most common mutation in this gene associated with Parkinson’s.
In the general population, this variant is relatively rare. However, its prevalence increases significantly in certain ethnic groups. For instance, approximately 1% to 2% of people with Parkinson’s of European descent carry this variant. Among those of Ashkenazi Jewish descent, the frequency rises to about 15% to 20%, and it is found in nearly 40% of North African Berber populations with the disease.
The GBA Gene (N370S Variant)
The GBA (Glucocerebrosidase) gene is responsible for an enzyme that breaks down a fatty substance called glucocerebroside. While mutations in this gene are the primary cause of Gaucher disease (a lysosomal storage disorder), having a single copy of certain GBA variants, such as N370S, is a significant risk factor for Parkinson’s.
The N370S variant is the most common GBA mutation screened by 23andMe. Like the LRRK2 variant, it is significantly more common in the Ashkenazi Jewish population. It is estimated that carrying one copy of this variant increases the risk of developing Parkinson’s by approximately five-fold compared to the general population.
The Concept of Incomplete Penetrance
One of the most critical distinctions in genetic health is the difference between a "causative" gene and a "risk" gene. Parkinson’s is largely characterized by incomplete penetrance, meaning that even if you carry a high-risk genetic variant, there is no guarantee you will ever develop the symptoms of the disease.
If you test positive for the G2019S variant in the LRRK2 gene, your lifetime risk increases, but it remains far from 100%. Studies have shown that the penetrance of this variant varies widely, with some estimates suggesting a 25% to 80% chance of developing the disease by age 80, depending on the study population and environmental factors. Many individuals carry these variants their entire lives and remain neurologically healthy.
This distinction is why 23andMe’s report is classified as a "Health Risk" report rather than a diagnostic tool. A diagnostic test confirms a condition; a risk report merely adjusts the statistical likelihood of a future event.
What the 23andMe Report Cannot Tell You
While the information provided by 23andMe is scientifically valid and FDA-authorized, it represents only a small fraction of the genetic landscape of Parkinson’s disease.
1. Other Genetic Variants
There are over 90 known genetic regions associated with Parkinson’s disease, and hundreds of rare variants within genes like PARK7, PINK1, and SNCA. 23andMe does not test for the vast majority of these. A "Variant Not Detected" result does not mean you have zero genetic risk; it simply means you do not have the two specific markers the company is equipped to find.
2. Idiopathic Parkinson’s
The majority of Parkinson’s cases—approximately 85% to 90%—are considered "idiopathic," meaning they occur in individuals with no known family history and no identifiable genetic cause. For most people, the disease is likely the result of a complex interplay between dozens of minor genetic predispositions and a lifetime of environmental exposures.
3. Environmental and Lifestyle Factors
Genetics load the gun, but the environment pulls the trigger. 23andMe cannot account for your exposure to pesticides (such as paraquat or rotenone), history of head trauma, or even protective factors like caffeine consumption or regular exercise. These non-genetic variables play a massive role in whether the disease actually manifests.
4. Age of Onset and Severity
Even if a genetic variant is present, the data cannot predict when symptoms might start or how quickly the disease will progress. Two people with the exact same LRRK2 mutation may have vastly different clinical experiences; one might develop a tremor at age 50, while the other might experience only mild gait changes at age 85.
Comparing 23andMe to Clinical Genetic Testing
If you have a strong family history of Parkinson’s, a consumer test might not be the most appropriate tool. Clinical-grade testing, often ordered by a neurologist or genetic counselor, offers a much deeper look into the genome.
| Feature | 23andMe (Consumer) | Clinical Genetic Testing |
|---|---|---|
| Method | Genotyping (SNP Chips) | Full Gene Sequencing or Targeted Panels |
| Variants Screened | 2 (LRRK2 G2019S, GBA N370S) | Dozens of genes and thousands of variants |
| Purpose | Wellness and Risk Education | Diagnosis and Clinical Management |
| FDA Status | Authorized for Health Risk reports | Validated for Clinical Diagnosis |
| Counseling | Educational resources only | Integrated with Genetic Counselors |
| Cost | Fixed kit price ($199–$229) | Varies (often covered by insurance) |
| Data Privacy | Subject to corporate privacy policy | Protected by HIPAA (in the U.S.) |
The Role of the Ashkenazi Jewish Ancestry
The 23andMe Parkinson's report is most informative for individuals of Ashkenazi Jewish descent. Because the LRRK2 G2019S and GBA N370S variants are so prevalent in this specific population, the test has a higher "utility" for these users.
If you do not have Ashkenazi Jewish, European, or North African Berber ancestry, the likelihood of carrying these specific mutations is extremely low. Consequently, a "Variant Not Detected" result for a person of East Asian or West African descent provides very little information regarding their actual genetic risk for Parkinson’s, as their risk might be driven by different, unmapped variants.
Ethical and Psychological Considerations
Receiving a report that indicates an increased risk for a progressive, incurable neurological disease can be distressing. Before opting into this specific report within the 23andMe dashboard, users should consider the following:
- The "Uncurable" Factor: Unlike high cholesterol or type 2 diabetes, there is currently no "cure" for Parkinson’s that can be triggered by a genetic discovery. While lifestyle changes can help, some individuals find the "pre-symptomatic" knowledge creates significant anxiety (often called "Scanxiety" or "Genetic Anxiety").
- Family Implications: Your DNA is shared. A positive result for you means your siblings, parents, and children may also carry the variant. This can lead to difficult conversations and unwanted disclosures within a family unit.
- Insurance and Discrimination: In the United States, the Genetic Information Nondiscrimination Act (GINA) protects individuals from genetic discrimination by health insurers and employers. However, GINA does not apply to life insurance, disability insurance, or long-term care insurance. A positive genetic risk report could theoretically impact your ability to secure these types of policies in the future.
How to Handle Your Results
If you have already received your 23andMe results and they show a detected variant, the next steps are crucial for your mental and physical well-being.
Step 1: Do Not Panic
Remember the concept of incomplete penetrance. A "detected" variant is not a diagnosis. Most people who carry these variants do not develop Parkinson’s.
Step 2: Consult a Genetic Counselor
A genetic counselor is trained to interpret these results in the context of your personal and family medical history. They can help you understand the true statistical risk and determine if further clinical testing is warranted. The National Society of Genetic Counselors provides directories to find professionals who specialize in neurology.
Step 3: Speak with a Neurologist
If you are experiencing symptoms—such as a resting tremor, stiffness, or loss of smell—you should consult a movement disorder specialist. They can perform a clinical exam, which remains the "gold standard" for Parkinson’s diagnosis.
Step 4: Contribute to Research
If you carry a variant, you are in a unique position to help scientists find a cure. Organizations like the Michael J. Fox Foundation and their PPMI (Parkinson’s Progression Markers Initiative) study specifically seek individuals with LRRK2 and GBA variants to understand how the disease develops before symptoms even appear.
The Future of Genetic Testing for Parkinson's
As of 2026, the field of neurogenetics is moving toward "Polygenic Risk Scores" (PRS). Instead of looking at just one or two mutations, PRS looks at thousands of tiny variations across the entire genome to create a more comprehensive risk profile. While 23andMe has begun integrating PRS for some conditions, the Parkinson’s report still relies primarily on the high-impact LRRK2 and GBA variants.
Research is also expanding into "Pharmacogenomics," where your genetic data might one day tell doctors which Parkinson’s medications will work best for you or which ones will cause the fewest side effects. Carrying a GBA mutation, for example, may eventually qualify patients for specific clinical trials testing drugs that target lysosomal function.
FAQs
Can 23andMe tell me if I definitely have Parkinson’s?
No. 23andMe cannot diagnose Parkinson’s disease. It only identifies whether you have specific genetic variants that increase your risk. A diagnosis can only be made through a clinical evaluation by a healthcare professional, typically a neurologist, based on symptoms and physical exams.
What if I have a family history of Parkinson’s but my 23andMe report is negative?
A negative result means you do not carry the G2019S or N370S variants. However, because these are only two of hundreds of potential genetic factors, a negative result does not rule out a hereditary link. If your family history is strong, you should seek a more comprehensive clinical genetic panel through a healthcare provider.
Is the 23andMe Parkinson’s test accurate?
The test is highly accurate at identifying the specific SNPs (G2019S and N370S) it is designed to find. 23andMe’s genotyping technology has been validated to meet FDA standards for analytical validity. However, its "clinical utility" is limited because it does not sequence the entire gene or look for other mutations.
Does 23andMe test for the "Parkinson’s gene"?
There is no single "Parkinson’s gene." The disease is associated with many different genes. 23andMe tests for variants in two of the most well-studied ones (LRRK2 and GBA), but these are only part of a much larger genetic puzzle.
Can I use my raw data to find more Parkinson’s risks?
Some users upload their 23andMe "Raw Data" to third-party tools to look for other variants. While this can provide more information, these third-party reports are often not FDA-cleared and may have higher rates of false positives. Always verify any findings from raw data tools with a clinical-grade test.
Practical Recommendation
If you are using 23andMe to explore your Parkinson's risk, treat the results as an educational starting point rather than a medical finality. If your report shows a detected variant, seek professional genetic counseling before making any life-altering decisions. If your report is negative but you remain concerned due to family history or symptoms, request a referral to a movement disorder specialist for a comprehensive clinical evaluation and potentially a more expansive genomic sequencing panel.
